Medical/Pharmaceuticals

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...

2021-10-12 20:30 1529

Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform

SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...

2021-10-12 19:21 2719

NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification

* Real-time PCR-based human papillomavirus (HPV) detection product is launched. * Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO,South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, annou...

2021-10-12 16:00 1774

Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, Oct. 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (O...

2021-10-11 13:00 6415

Winhealth-CARD Cooperation Boosts Rare Disease Healthy Ecosystem Construction

BOAO, China, Oct. 8, 2021 /PRNewswire/ -- On September 30, 2021 (Hainan-Bo'ao), Hongkong Winhealth Pharma Group (Winhealth Pharma) and the China Alliance for Rare Disease (CARD) officially signed a five-year strategic collaboration agreement. The cooperation involved rare disease registration and...

2021-10-08 23:01 3984

ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference

WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Res...

2021-10-08 11:39 2769

Medtecs participates for the first time in world's leading nonwovens exhibition - INDEX(TM)20 in Europe

TAIPEI, Oct. 7, 2021 /PRNewswire/ -- The threat of COVID-19 continues. As vaccine development fails to keep up with the rate the virus mutates, countries around the world have started exploring ways to "coexist with the virus," meaning that personal protective equipment (PPE) such as face masks a...

2021-10-07 21:28 4701

Kazia Therapeutics to Present at LD Micro Main Event

SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from12-14 October 2021. Since...

2021-10-06 22:00 8314

VUNO Signs Another Deal with Samsung Electronics to Incorporate AI-assisted Solutions into Samsung's Premium Ceiling Type Digital Radiography System

SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today that the company closed a deal with global medical device manufacturer, Samsung Electronics Co., Ltd., to embed VUNO's artificial intelligence-driven chest X-ray diagno...

2021-10-05 21:00 3400

I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Kor...

2021-10-05 20:00 9499

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at t...

2021-10-05 18:00 1994

Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US

SUZHOU, China, Oct. 4, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that onOctober 1 its phase III clinical trial of proxalutamide for the ...

2021-10-04 16:30 10255

Joint Commission International Publishes Second Edition of International Accreditation Standards for Home Care

Standards and requirements in latest edition become effective 1 April 2022 OAK BROOK, Ill., Oct. 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Home Care, Second Edition. The manual provides home care organiza...

2021-10-01 20:00 2718

I-Mab Announces Upcoming Participation at October Conferences

SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...

2021-10-01 20:00 14725

Binhai sets ambitious biomedical goals with support of key companies

TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...

2021-10-01 01:08 1835

Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- RVAC Medicines  Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company inSingapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the to...

2021-10-01 00:50 2325

LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH

SEOUL, South Korea, Sept. 30, 2021 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it has received approval for a global phase 1 clinical trial for two programs, LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. This achievement i...

2021-09-30 21:00 1777

uMR OMEGA™ Recognized in Fast Company's 2021 Innovation by Design Awards

HOUSTON, Sept. 30, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, was honored inFast Company's2021 Innovation by Design Awards for its groundbreaking magnetic resonance system, the uMR OMEGA. The 10th anniversary of the awards, which ...

2021-09-30 21:00 1704

Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials

SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. ("Evergreen"), a radiopharmaceutical...

2021-09-30 20:03 1761

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021The current U.S. NHL clinical trial has now expanded to include clinical sites inChina as an international multi-center clinical trial, which will potentially lead to a r...

2021-09-30 20:00 6601
1 ... 221222223224225226227 ... 251

Week's Top Stories